Deerfield, Ill.-based Baxter International reported results from two health economic analyses regarding its FLOSEAL Hemostatic Matrix.
FLOSEAL Hemostatic Matrix is intended to control bleeding during cardiac and spinal surgeries, indicated for use as an adjunct to "hemostasis when control of bleeding by ligature or conventional procedure is ineffective or impractical."
Journal of Medical Economics published the studies.
Spinal surgery analysis
1. Researches discovered potential hospital cost savings of $151 per major and $574 per severe spinal surgery when using FLOSEAL, compared to using Somerville, N.J.-based Ethicon's SURGIFLO.
2. Hospitals would reap these savings with FLOSEAL due to shorter operative room time, a lower blood transfusion rate and lower product volume use.
Cardiac surgery analysis
3. Researchers compared potential cost savings when using FLOSEAL versus SURGIFLO, and found savings of $1.5 million annually for an average U.S. hospital.
4. The savings would result from fewer major and minor complications, surgical revisions, blood product transfusions and operating time hours.